Clavulanate Potassium
FDA-approved product (tablet, oral).
- Registered studies
- 50+
- Lab records
- 28
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Infection
- Infectious otitis media
- Otitis media
- Pneumonia
- Respiratory tract infectious disorder
- Sinusitis
- Soft Tissue Infections
- Urinary tract infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Combinations of penicillins, incl. beta-lactamase inhibitors
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01CR02
Repurposing investigation
Clavulanate Potassium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA4.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli74.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae73.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- MRSA: measured active in 1 of 8 lab records
- E. coli: measured active in 9 of 16 lab records
- K. pneumoniae: measured active in 4 of 4 lab records
Show the 28 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Clavulanate Potassium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pipecuronium BromideExisting use: Other quaternary ammonium compounds42.9% AI-predicted activityagainst K. pneumoniae5 registered studies
- Fosaprepitant DimeglumineExisting use: Cancer, Chemotherapy-induced nausea and vomiting, Nausea and 3 more42.9% AI-predicted activityagainst K. pneumoniae21 registered studies
- CabergolineExisting use: Hypothalamic neoplasm, Parkinson disease42.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Fondaparinux SodiumExisting use: Deep vein thrombosis, Intermediate coronary syndrome, Myocardial infarction and 3 more42.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder42.6% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Vecuronium BromideExisting use: Other quaternary ammonium compounds42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease42.0% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- Lumateperone TosylateExisting use: Psychosis, Schizophrenia41.9% AI-predicted activityagainst K. pneumoniae6 registered studies
- RepotrectinibExisting use: Cancer, Neoplasm41.8% AI-predicted activityagainst K. pneumoniae17 registered studies
- MoxidectinExisting use: Helminthiasis, Onchocerciasis41.7% AI-predicted activityagainst K. pneumoniae25 registered studies
- PralsetinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 1 more41.5% AI-predicted activityagainst K. pneumoniae19 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients
NCT00354965 · start 2006-01-19
Registered record
- Registry ID
- NCT00354965
- Conditions
- Infections, Respiratory Tract
- Interventions
- amoxicillin/clavulanate potassium
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-01-19
- Completion
- 2007-04-02
- Enrolment
- 52
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfections, Respiratory TractInterventionamoxicillin/clavulanate potassiumPhasePhase 1Registry statusCompletedGuidelines for Acute Sinusitis
NCT00132275 · start 2003-11
Registered record
- Registry ID
- NCT00132275
- Conditions
- Sinusitis
- Interventions
- Amoxicillin potassium clavulanate
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2003-11
- Completion
- 2006-08
- Enrolment
- 240
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSinusitisInterventionAmoxicillin potassium clavulanatePhaseNot applicableRegistry statusCompletedBioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions
NCT00778661 · start 2002-10
Registered record
- Registry ID
- NCT00778661
- Conditions
- Healthy
- Interventions
- amoxicillin 400mg + clovalunic acid 57.5mg tablets
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2002-10
- Completion
- 2002-12
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionamoxicillin 400mg + clovalunic acid 57.5mg tabletsPhaseNot applicableRegistry statusCompletedEarly-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment
NCT01559753 · start 1998-01
Registered record
- Registry ID
- NCT01559753
- Conditions
- Pneumonia Ventilator Associated
- Interventions
- Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin; compare 8 to15 days of antibiotic treatment
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 1998-01
- Completion
- 2002-11
- Enrolment
- 225
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumonia Ventilator AssociatedInterventionAugmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin; compare 8 to15 days of antibiotic treatmentPhasePhase 4Registry statusCompletedAcupuncture and Herbal Treatment of Chronic HIV Sinusitis
NCT00002149
Registered record
- Registry ID
- NCT00002149
- Conditions
- HIV Infections; Sinusitis
- Interventions
- Clavulanate potassium; Pseudoephedrine hydrochloride; Amoxicillin trihydrate
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections; SinusitisInterventionClavulanate potassium; Pseudoephedrine hydrochloride; Amoxicillin trihydratePhaseNot applicableRegistry statusCompleted